Zerbaxa Trial Hits Endpoints Treating HAP, VAP

Zerbaxa (ceftolozane and tazobactam) demonstrated non-inferiority to meropenem in 28-day all-cause mortality in the treatment of hospital-acquired pneumonia or ventilator-associated pneumonia.